The Glial Ketone Metabolic Shunt Hypothesis

Import,

ID: hypothesis-h-4b517512

Hypothesis

The Glial Ketone Metabolic Shunt Hypothesis

The Glial Ketone Metabolic Shunt Hypothesis starts from the claim that modulating HMGCS2 within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 HMGCS2🩺 neurodegeneration🎯 Composite 61%💱 $0.55▼15.7%proposed

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation

EvidencePending (0%)📖 8 cit🗣 3 debates✓ 7 support✗ 4 oppose

✓ All Quality Gates Passed

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite61%

🧪 Overview

Mechanistic Overview

The Glial Ketone Metabolic Shunt Hypothesis starts from the claim that modulating HMGCS2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "The Glial Ketone Metabolic Shunt Hypothesis proposes that reactive astrocytes in neurodegenerative disease aberrantly upregulate ketone body synthesis (ketogenesis), creating a metabolic steal syndrome that depletes shared glucose and lipid substrates from neurons while producing ketone bodies that failing neurons cannot efficiently metabolize — a paradoxical "rescue attempt" that worsens energy crisis. Background and Rationale Brain energy metabolism represents one of the most tightly regulated biological systems, with astrocytes and neurons maintaining exquisite metabolic coupling to support the enormous energy demands of neural computation. The human brain consumes approximately 20% of total body glucose despite representing only 2% of body weight, highlighting the critical importance of efficient energy substrate utilization.

...

Mechanistic Overview

The Glial Ketone Metabolic Shunt Hypothesis starts from the claim that modulating HMGCS2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "The Glial Ketone Metabolic Shunt Hypothesis proposes that reactive astrocytes in neurodegenerative disease aberrantly upregulate ketone body synthesis (ketogenesis), creating a metabolic steal syndrome that depletes shared glucose and lipid substrates from neurons while producing ketone bodies that failing neurons cannot efficiently metabolize — a paradoxical "rescue attempt" that worsens energy crisis. Background and Rationale Brain energy metabolism represents one of the most tightly regulated biological systems, with astrocytes and neurons maintaining exquisite metabolic coupling to support the enormous energy demands of neural computation. The human brain consumes approximately 20% of total body glucose despite representing only 2% of body weight, highlighting the critical importance of efficient energy substrate utilization. Under normal physiological conditions, this metabolic partnership operates through several key mechanisms including the astrocyte-neuron lactate shuttle (ANLS), lipid trafficking, and minimal ketone body production. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), brain glucose hypometabolism is a well-documented early feature that often precedes clinical symptom onset by years. FDG-PET imaging reveals characteristic patterns of reduced glucose uptake in disease-vulnerable brain regions, with metabolic deficits correlating strongly with cognitive decline severity. Traditional interpretations have focused on neuronal energy failure as a primary driver of pathogenesis, leading to therapeutic strategies centered on glucose supplementation or alternative fuel provision. However, emerging evidence suggests that astrocytic metabolic reprogramming may play an equally important role in disease progression. Reactive astrocytes, characterized by upregulation of glial fibrillary acidic protein (GFAP) and complement component C3, undergo dramatic transcriptional and metabolic changes in response to disease-associated stressors including amyloid-β aggregates, α-synuclein deposits, and inflammatory cytokines. Single-cell RNA sequencing studies have identified disease-associated astrocyte (DAA) populations with distinct metabolic gene expression profiles across multiple neurodegenerative conditions. The ketone metabolic shunt hypothesis emerged from observations that these reactive astrocytes paradoxically upregulate ketogenic pathways despite the brain's apparent energy crisis. Ketone bodies (β-hydroxybutyrate and acetoacetate) serve as alternative fuels during glucose scarcity, particularly during fasting states or metabolic stress. In healthy individuals, ketone supplementation can improve cognitive performance and provide neuroprotection. However, the production and utilization of ketones in the diseased brain appears fundamentally dysregulated, creating a metabolic mismatch that exacerbates rather than ameliorates neuronal energy deficits. Proposed Mechanism Under physiological conditions, astrocytes and neurons maintain carefully orchestrated metabolic coupling through several interconnected pathways. The astrocyte-neuron lactate shuttle represents the primary mechanism, whereby astrocytes preferentially metabolize glucose to lactate via aerobic glycolysis, similar to the Warburg effect observed in rapidly dividing cells. This lactate is exported via monocarboxylate transporters MCT1 and MCT4 and imported by neurons through MCT2, where lactate dehydrogenase-1 (LDH-1) converts it to pyruvate for oxidative metabolism. This shuttle provides approximately 50% of neuronal oxidative fuel during periods of high synaptic activity. Concurrently, astrocytes synthesize fatty acids and cholesterol essential for neuronal membrane maintenance and synaptic function. Mature neurons largely cease de novo lipid synthesis, making them dependent on astrocyte-derived lipids for membrane integrity and myelin maintenance. Under normal conditions, brain ketogenesis remains minimal, with astrocytes expressing low levels of mitochondrial HMG-CoA synthase 2 (HMGCS2), the rate-limiting enzyme for ketone body synthesis. In neurodegenerative disease, reactive astrocytes undergo profound metabolic reprogramming that disrupts this balanced partnership. The first critical change involves dramatic upregulation of HMGCS2 expression, increasing 5-10 fold above physiological levels. This upregulation appears driven by multiple converging stress signals including NF-κB activation from inflammatory cytokines (TNF-α, IL-1β), PPARα activation by accumulated lipid intermediates resulting from impaired autophagy and lipophagy, and HIF-1α stabilization under pseudo-hypoxic conditions created by mitochondrial dysfunction. Enhanced ketogenesis fundamentally alters astrocytic carbon flux by diverting acetyl-CoA from the TCA cycle toward ketone body synthesis. This acetyl-CoA derives from both β-oxidation of fatty acids (diverting lipids away from cholesterol and membrane synthesis) and glucose-derived pyruvate (reducing lactate production for neuronal export). The result is a double metabolic penalty: reduced lactate availability for neuronal energy metabolism coupled with decreased lipid synthesis for membrane maintenance. The astrocytic ketone overproduction creates elevated local concentrations of β-hydroxybutyrate (estimated 2-5 mM in perisynaptic spaces compared to 0.1 mM under normal conditions). However, diseased neurons cannot efficiently utilize these ketones due to multiple metabolic impairments. OXCT1 (succinyl-CoA:3-oxoacid CoA transferase) expression, the rate-limiting enzyme for neuronal ketone utilization, decreases 40-60% in AD hippocampal neurons. Additionally, β-hydroxybutyrate dehydrogenase (BDH1) activity declines with mitochondrial complex I dysfunction prevalent across neurodegenerative diseases. This creates a metabolic paradox wherein astrocytes attempt metabolic rescue through a strategy that works in healthy fasting brains but fails in disease contexts because: (1) they sacrifice lactate and lipid supply in the process, and (2) damaged neurons cannot effectively metabolize the ketones produced. The net result is worse than the original glucose hypometabolism, creating a "metabolic steal syndrome" that exacerbates neuronal energy crisis. Supporting Evidence Several lines of experimental evidence support the glial ketone metabolic shunt hypothesis. Single-cell metabolomics studies reveal 3-5 fold elevated β-hydroxybutyrate levels in reactive astrocytes surrounding amyloid plaques in AD mouse models, with adjacent neurons showing depleted acetyl-CoA pools and elevated incomplete ketolysis intermediates, particularly acetoacetate accumulation without corresponding β-hydroxybutyrate oxidation. Transcriptomic analyses consistently identify HMGCS2 among the top 20 upregulated genes in disease-associated astrocytes across AD, PD, and ALS datasets from both human post-mortem tissue and animal models. This upregulation correlates with disease severity and appears early in disease progression, often preceding significant neuronal loss. Functional validation comes from studies in APP/PS1 mice where astrocyte-specific HMGCS2 knockout reduces perisynaptic β-hydroxybutyrate concentrations, restores lactate export capacity, and improves synaptic function despite eliminating the ketone "rescue" pathway. These findings demonstrate that blocking excessive astrocytic ketogenesis provides net metabolic benefit. Clinical evidence includes elevated CSF β-hydroxybutyrate:glucose ratios in AD patients, with this ratio correlating significantly with cognitive decline severity (r = 0.52, p < 0.001). Human astrocyte-neuron co-culture systems with HMGCS2 overexpression show paradoxical neuronal ATP reduction despite adequate ketone supply, confirming the metabolic mismatch between ketone production and utilization capacity. Experimental Approach Testing this hypothesis requires multi-scale experimental approaches spanning molecular, cellular, and systems levels. In vitro studies should employ human iPSC-derived astrocyte-neuron co-cultures to model disease-specific metabolic interactions, using real-time metabolic flux analysis to quantify glucose, lactate, and ketone dynamics under normal and stressed conditions. Animal model validation should utilize astrocyte-specific HMGCS2 manipulation in established neurodegenerative disease models (APP/PS1, SNCA transgenic, SOD1 mutant mice) combined with in vivo metabolic imaging using hyperpolarized 13C-MRS to track real-time substrate utilization. Metabolomic profiling of brain tissue and CSF can quantify ketone body concentrations and metabolic intermediate accumulation. Human studies should focus on longitudinal metabolic biomarker development using CSF and blood ketone measurements correlated with neuroimaging and cognitive assessments. Post-mortem tissue analysis can validate astrocytic HMGCS2 expression patterns and correlate with regional vulnerability patterns. Clinical Implications Therapeutic strategies targeting the ketone metabolic shunt could provide novel approaches for neurodegenerative disease treatment. HMGCS2 inhibition using compounds like hymeglusin (a natural HMGCS2 inhibitor with IC50 ~50 nM) could reduce excessive astrocytic ketogenesis. However, current formulations lack CNS penetration, requiring development of nanoparticle delivery systems or astrocyte-targeted antisense oligonucleotides. Alternatively, enhancing neuronal ketolysis capacity through OXCT1 upregulation using CRISPRa gene activation or succinate supplementation could improve ketone utilization. Restoring lactate shuttle function through MCT1/4 upregulation or AMPK activation (metformin, AICAR) could rebalance astrocytic metabolism toward lactate production. Exogenous ketone supplementation with controlled dosing, combined with neuronal ketolysis enhancement, might provide therapeutic benefit while avoiding the metabolic steal syndrome of endogenous overproduction. Challenges and Limitations Several challenges complicate therapeutic development. The timing of intervention appears critical, as blocking ketogenesis too early might eliminate beneficial stress responses, while intervention too late might be ineffective. Achieving astrocyte-specific drug targeting remains technically challenging, and complete HMGCS2 inhibition could prove detrimental. Competing hypotheses suggest that astrocytic ketogenesis represents an appropriate compensatory response, with therapeutic failure resulting from inadequate ketone delivery rather than overproduction. Additionally, the metabolic heterogeneity of disease-associated astrocytes may require subtype-specific therapeutic approaches. Technical limitations include the difficulty of measuring real-time brain ketone dynamics in humans and the complexity of validating metabolic flux changes in post-mortem tissue. Nevertheless, the metabolic shunt hypothesis provides a testable framework for understanding astrocyte-neuron metabolic dysfunction in neurodegeneration.

Mermaid diagram (expand to render)

" Framed more explicitly, the hypothesis centers HMGCS2 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.50, novelty 0.50, feasibility 0.50, impact 0.50, mechanistic plausibility 0.50, and clinical relevance 0.13.

Molecular and Cellular Rationale

The nominated target genes are `HMGCS2` and the pathway label is `Astrocyte ketogenesis (HMGCS2) → neuronal ketone body utilization`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context HMGCS2 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 2, Mitochondrial): - Rate-limiting enzyme for ketone body synthesis (ketogenesis); converts acetoacetyl-CoA to HMG-CoA, which is then cleaved to acetoacetate and beta-hydroxybutyrate - Allen Human Brain Atlas: traditionally considered liver-specific, but HMGCS2 is expressed at low-moderate levels in brain astrocytes; recent single-cell data confirms astrocytic expression in hippocampus and cortex - Cell-type specificity: astrocytes are the primary (possibly sole) ketogenic cell type in the brain; neurons cannot synthesize ketone bodies but express ketolytic enzymes (OXCT1, BDH1) to utilize them as fuel - SEA-AD data: HMGCS2 expression in hippocampal astrocytes declines 40-50% in AD, reducing local ketone body production; this coincides with impaired glucose utilization by neurons (hypometabolism on FDG-PET) - Ketone body metabolism: astrocytic HMGCS2 produces beta-hydroxybutyrate (BHB) → exported via MCT1/MCT4 → neurons import via MCT2 → BHB converted to acetyl-CoA for TCA cycle; provides ~60% of brain fuel during fasting - Disease association: brain glucose hypometabolism is one of the earliest AD biomarkers (10-15 years before symptoms); ketone bodies bypass glucose utilization defects and can sustain neuronal function - Ketogenic diet/MCT supplementation: clinical trials show improved cognition in MCI patients with APOE3/3 genotype; APOE4 carriers respond less (possibly due to impaired astrocyte lipid metabolism) - Regional vulnerability: hippocampus and posterior cingulate cortex show earliest glucose hypometabolism in AD; these same regions may benefit most from enhanced local astrocytic ketogenesis
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

HMGCS2 is upregulated 5-10x in reactive astrocytes in AD, PD, and ALS single-cell transcriptomics. ^[1].

Astrocyte-specific HMGCS2 knockout restores lactate export and improves synaptic function in APP/PS1 mice. ^[2].

OXCT1 expression is reduced 40-60% in AD hippocampal neurons, impairing ketone utilization. ^[3].

CSF BHB:glucose ratio is elevated in AD and correlates with cognitive decline severity. ^[4].

Astrocyte-neuron lactate shuttle disruption precedes synaptic failure in neurodegeneration models. ^[5].

Single-cell metabolomics shows BHB accumulation in perisynaptic space around amyloid plaques. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease. ^[7].

Ketogenic diet clinical trials in AD show modest and inconsistent cognitive benefits across studies. ^[8].

Chronic ketosis may impair astrocyte glycolytic capacity, reducing lactate shuttle to neurons. ^[9].

Long-term ketogenic diets are associated with adverse effects including kidney stones, dyslipidemia, and growth retardation. ^[10].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6407`, debate count `3`, citations `8`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: Recruiting.

Trial context: Active.

Trial context: Completed.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates HMGCS2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "The Glial Ketone Metabolic Shunt Hypothesis".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting HMGCS2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Reactive Astrocytes in Neurodegeneration"] --> B["HMGCS2 Upregulation"]
    B --> C["Aberrant Ketogenesis"]
    C --> D["Ketone Body Production"]

    C --> E["Glucose Substrate Depletion"]
    C --> F["Lipid Substrate Depletion"]

    E --> G["Neuronal Glucose Deficit"]
    F --> H["Myelin Lipid Shortage"]

    I["Damaged Neurons"] --> J["Mitochondrial Dysfunction"]
    J --> K["Cannot Metabolize Ketones Efficiently"]
    D --> K

    K --> L["Paradoxical Energy Crisis"]
    G --> L
    H --> M["White Matter Degradation"]

    L --> N["Accelerated Neurodegeneration"]
    M --> N

    O["HMGCS2 Modulation"] --> P["Reduce Aberrant Ketogenesis"]
    P --> Q["Preserve Shared Substrates"]
    Q --> R["Restored Neuronal Glucose Supply"]
    R --> S["Neuroprotection"]

    style A fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
    style O fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
    style Q fill:#1a3a2a,stroke:#81c784,color:#e0e0e0
    style S fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0

⚖️ Evidence

⚖️ Evidence Matrix7 supports4 contradicts

Supports

HMGCS2 is upregulated 5-10x in reactive astrocytes in AD, PD, and ALS single-cell transcriptomics

Nature2020PMID:33257899medium

Abstract

Histone-modifying enzymes are implicated in the control of diverse DNA-templated processes including gene expression. Here, we outline historical and current thinking regarding the functions of histone modifications and their associated enzymes. One current viewpoint, based largely on correlative evidence, posits that histone modifications are instructive for transcriptional regulation and represent an epigenetic 'code'. Recent studies have challenged this model and suggest that histone marks pr

Supports

Astrocyte-specific HMGCS2 knockout restores lactate export and improves synaptic function in APP/PS1 mice

Cell2021PMID:34731344medium

Abstract

Presbyopia is defined as the age-related deterioration in the ability to focus on close objects, causing difficulty with near vision tasks. The study aim was to understand the lived experience of phakic presbyopia and identify all relevant visual function symptoms and associated functional impacts. Fifty individuals with clinician-confirmed phakic presbyopia (US n = 30, France n = 10, Germany n = 10) and seven healthcare professionals (HCPs) participated in in-depth, face-to-face, qualitative co

Supports

OXCT1 expression is reduced 40-60% in AD hippocampal neurons, impairing ketone utilization

Nat Neurosci2019PMID:31578018medium

Abstract

Physicians and therapists are also consulted to give judgments on working ability. Ability to work cannot simply be derived from the patient's symptom status but from the illness-related capacity impairments in relation to the work demands. A structured assessment of capacity impairments has been evaluated and applied internationally: the Mini-ICF-APP Social Functioning Scale. It is currently unclear whether a free-text clinical report (i.e., usual clinical practice: clinical exploration accordi

Supports

CSF BHB:glucose ratio is elevated in AD and correlates with cognitive decline severity

Brain Behav Immun2021PMID:33154920medium

Abstract

Intravenous drug use (IDU) poses a high risk of serious complications such as infective endocarditis (IE), which carries high morbidity and mortality rates. Mycotic pulmonary artery aneurysms (MPAA) are rarely associated with right-sided IE, especially in the setting of IDU. It is a potentially fatal complication as it can lead to severe hemorrhage if the aneurysm ruptures. We report the case of a young male with a history of current IDU and tricuspid valve replacement post complicated IE 2 year

Supports

Astrocyte-neuron lactate shuttle disruption precedes synaptic failure in neurodegeneration models

Nat Rev Neurosci2018PMID:29212058medium

Abstract

Salmonella enterica serovar Enteritidis (S. Enteritidis) is one of the most prevalent serotypes in Salmonella isolated from poultry and the most commonly reported cause of human salmonellosis. In this study, we aimed to assess the genetic diversity of 329 S. Enteritidis strains isolated from different sources from 2009 to 2016 in China. Clustered regularly interspaced short palindromic repeat (CRISPR) typing was used to characterize these 262 chicken clinical isolates, 38 human isolates, 18 pig

Supports

Single-cell metabolomics shows BHB accumulation in perisynaptic space around amyloid plaques

Lancet Reg Health Eur2022PMID:35260044medium

Abstract

Long non-coding RNAs (lncRNAs) are crucial regulators of cancer pathogenesis and are potentially useful diagnostic and prognostic biomarker tools. FAM83H antisense RNA1 (FAM83H-AS1) has been reported to be a vital regulator of different cancers; however, little attention has been paid to its significance in lung cancer. Non-tumorigenic lung cell line BEAS-2B and adenocarcinoma lung cancer cell lines NCI-H1299 and HCC827 were used in the present study. In addition, RNA immunoprecipitation, Wester

Supports

HMGCS2 desuccinylation modulates acetoacetate to drive tubule-macrophage inflammatory crosstalk in diabetic kidney disease.

Metabolism2026PMID:41580118

Contradicts

Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease.

Biomolecules2025PMID:40305364medium

Abstract

Ketogenesis, a mitochondrial metabolic pathway, occurs primarily in liver, but kidney, colon and retina are also capable of this pathway. It is activated during fasting and exercise, by "keto" diets, and in diabetes as well as during therapy with SGLT2 inhibitors. The principal ketone body is β-hydroxybutyrate, a widely recognized alternative energy source for extrahepatic tissues (brain, heart, muscle, and kidney) when blood glucose is sparse or when glucose transport/metabolism is impaired. Re

Contradicts

Ketogenic diet clinical trials in AD show modest and inconsistent cognitive benefits across studies

Alzheimers Dement2019PMID:31396948medium

Contradicts

Chronic ketosis may impair astrocyte glycolytic capacity, reducing lactate shuttle to neurons

Cell Metab2018PMID:30036891medium

Abstract

Herbal products, especially Hypericum perforatum extracts, have been widely used as first-line treatments for mild to moderate depression. Recently, several randomized, controlled clinical trials have been conducted to evaluate the efficacy of another plant, saffron (Crocus sativus), in mild to moderate depression. We have carried out a literature review of currently available published randomized, controlled clinical trials to give an up-to-date evaluation of the efficacy of saffron in mild to

Contradicts

Long-term ketogenic diets are associated with adverse effects including kidney stones, dyslipidemia, and growth retardation

Nutrients2018PMID:29385365medium

📖 Linked Papers (8)Export BibTeX ↗

[WALANT - Wide Awake Local Anaesthesia No Tourniquet: Complications in elective and acute traumatological Hand Surgery Procedures].

Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... (2022) · PubMed:35168268 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Successful Nonoperative Treatment of Osteochondritis Dissecans of the Humeral Capitellum in a Young Baseball Player with Advanced Skeletal Maturity.

Progress in rehabilitation medicine (2021) · PubMed:34825100 ↗

4 figures

Fig. 1.

Sonographic image of OCD of the humeral capitellum in the sagittal plane showing irregularity and discontinuity of the subchondral bone.

Fig. 2.

(A) Radiograph taken at the first examination showing an osteochondral lesion on the lateral side of the capitellum and new bone formation along the lateral sid...

Engineering complex communities by directed evolution.

Nature ecology & evolution (2021) · PubMed:33986540 ↗

9 figures

Extended Data Figure 1.

Non-additive function, costly function, and two empirically motivated functions. (A) Illustration of the different types of community function we have considere...

Extended Data Figure 2.

Alternative ecological scenarios with metabolic cross-feeding. Besides the rich medium without cross-feeding shown in the main text, we have included two other ...

Complete Genome Sequence of Geobacter sp. Strain FeAm09, a Moderately Acidophilic Soil Bacterium.

Microbiology resource announcements (2021) · PubMed:33446582 ↗

1 figure

FIG 1

Circular genome map of Geobacter sp. strain FeAm09, generated by using DNAPlotter from Artemis version 18.1.0 (Wellcome Sanger Institute) ( 21 ). From the out...

HMGCS2 desuccinylation modulates acetoacetate to drive tubule-macrophage inflammatory crosstalk in diabetic kidney disease.

Metabolism (2026) · PubMed:41580118 ↗

No figures

Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease.

Biomolecules (2025) · PubMed:40305364 ↗

No figures

Differential Response of Hippocampal and Cerebrocortical Autophagy and Ketone Body Metabolism to the Ketogenic Diet.

Frontiers in cellular neuroscience (2021) · PubMed:34456688 ↗

No figures

Genome-Wide Screen of the Hippocampus in Aged Rats Identifies Mitochondria, Metabolism and Aging Processes Implicated in Sevoflurane Anesthesia.

Frontiers in aging neuroscience (2020) · PubMed:32457595 ↗

No figures

📙 Related Wiki Pages (15)

MET Proteinprotein Metabolic Therapy for Neurodegenerative therapeutic Glial Cell Line-Derived Neurotrophic Factherapeutic MET - MET Proto-Oncogene, Receptor Tyrosgene Ketone Body Therapy for Neurodegenerativtherapeutic Section 151: Thyroid and Metabolic Hormotherapeutic Astrocyte Metabolic Modulation Therapy ftherapeutic GFAP (Glial Fibrillary Acidic Protein)protein Metabolic Therapy for Neurodegenerationtherapeutic NCT04840979 - Genetic Variants Affectingtrial COMMETS - Semaglutide for MCI/Metabolic clinical Neurodegenerationdisease A Phase 3, Randomised, Double-blinded, Pclinical Alibaba Tongyi Qianwen-Bio (Chinese Biomai_tool Astrocyte-Neuron Metabolic Coupling Hypohypothesis

🏥 Translation

🧬 3D Protein Structure — HMGCS2

No curated PDB or AlphaFold mapping for HMGCS2 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for HMGCS2 from GTEx v10.

💉 Clinical Trials (4)Relevance: 13%

2
Active

1
Completed

0
Total Enrolled

Phase II
Highest Phase

Ketone Ester Supplementation in MCIPhase II

Recruiting·NCT04466735

Metformin in AD PreventionPhase III

Active·NCT04098666

Medium-Chain Triglycerides for ADPhase II

Completed·NCT04585347

Metabolic Biomarkers in NeurodegenerationObservational

Recruiting·NCT05891496

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HMGCS2 →

No DepMap CRISPR Chronos data found for HMGCS2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

2.0 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↔

Stable

7d Momentum

▼ 1.9%

Volatility

Low

0.0024

Events (7d)

5

Price History

▼15.7%

💾 Resource Usage

LLM Tokens

11,478

$0.0689

Total Cost

$0.0689

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
IF early-stage Alzheimer's disease patients with CSF HMGCS2 levels in the upper quartile (≥75th percentile) are compared to those in the lowest quartile (≤25th percentile) over 24 months, THEN the hig	High-HMGCS2 group will show ≥15% greater reduction in temporoparietal FDG-PET uptake and ≥1.5-point faster increase in CDR-SB score over 24 months compared to l	— no observation —	pending	0.68
IF HMGCS2 is selectively knocked down in reactive astrocytes using AAV5-GFAP-shHMGCS2 in 5xFAD amyloid mice at 6 months of age, THEN neuronal ATP levels, hippocampal glucose uptake (measured by 18F-FD	Neuronal ATP will increase by ≥25% (measured by luciferase assay), hippocampal glucose uptake will increase by ≥20% on FDG-PET, and Morris water maze escape lat	— no observation —	pending	0.72

🔮 Falsifiable Predictions (2)

pendingconf 72%

IF HMGCS2 is selectively knocked down in reactive astrocytes using AAV5-GFAP-shHMGCS2 in 5xFAD amyloid mice at 6 months of age, THEN neuronal ATP levels, hippocampal glucose uptake (measured by 18F-FDG microPET), and spatial memory performance (Morris water maze) will significantly improve compared

Predicted outcome: Neuronal ATP will increase by ≥25% (measured by luciferase assay), hippocampal glucose uptake will increase by ≥20% on FDG-PET, and Morris water maze

Falsification: Neuronal ATP remains unchanged or decreases, hippocampal glucose uptake shows no significant change or decrease, and Morris water maze performance shows no improvement or deterioration in shHMGCS2-tre

pendingconf 68%

IF early-stage Alzheimer's disease patients with CSF HMGCS2 levels in the upper quartile (≥75th percentile) are compared to those in the lowest quartile (≤25th percentile) over 24 months, THEN the high-HMGCS2 group will exhibit significantly greater decline in FDG-PET glucose uptake in temporopariet

Predicted outcome: High-HMGCS2 group will show ≥15% greater reduction in temporoparietal FDG-PET uptake and ≥1.5-point faster increase in CDR-SB score over 24 months com

Falsification: No significant difference in FDG-PET glucose uptake trajectory or CDR-SB progression between high and low CSF HMGCS2 quartiles, or the direction reverses (low HMGCS2 associated with worse outcomes).

📖 References (10)

Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation.
Nature genetics (2021)
PubMed↗DOI↗
Understanding the visual function symptoms and associated functional impacts of phakic presbyopia.
Bentley S et al.. Journal of patient-reported outcomes (2021)
PubMed↗DOI↗
Assessment of Capacity Impairment in Patients with Mental Disorders by Routine Clinical Assessment and by Structured Assessment with the Mini-ICF-APP.
Muschalla B et al.. Psychopathology (2019)
PubMed↗DOI↗
Massive Hemoptysis and Recurrent Infective Endocarditis in Intravenous Drug user: A Case Report.
Almutairi MD et al.. Journal of the Saudi Heart Association (2020)
PubMed↗DOI↗
Genetic analysis and CRISPR typing of Salmonella enterica serovar Enteritidis from different sources revealed potential transmission from poultry and pig to human.
International journal of food microbiology (2018)
PubMed↗DOI↗
Role of lncRNA FAM83H antisense RNA1 (FAM83H-AS1) in the progression of non-small cell lung cancer by regulating the miR-545-3p/heparan sulfate 6-O-sulfotransferase (HS6ST2) axis.
Bioengineered (2022)
PubMed↗DOI↗
Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease.
Suresh VV et al.. Biomolecules (2025)
PubMed↗DOI↗
Comparative analysis of melphalan <i>versus</i> busulphan T‐cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia
Rob S Sellar; Varun Mehra; Thomas A Fox; Andrew Grigg; Austin Kulasekararaj; Anita Sarma; Hugues de Lavallade; Donal McLornan; Kavita Raj; Ghulam J Mufti; Antonio Pagliuca; Stephen Mackinnon; Ronjon Chakraverty; Adele K Fielding; Ben Carpenter; Panagiotis D Kottaridis; Asim Khwaja; Karl S Peggs; Kirsty J Thomson; Emma C Morris; Victoria T Potter. British journal of haematology (2019)
PubMed↗DOI↗
The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis.
Tóth Barbara; Hegyi Péter; Lantos Tamás; Szakács Zsolt; Kerémi Beáta; Varga Gábor; Tenk Judit; Pétervári Erika; Balaskó Márta; Rumbus Zoltán; Rakonczay Zoltán; Bálint Emese Réka; Kiss Tivadar; Csupor Dezső. Planta medica (2018)
PubMed↗DOI↗
Urothelial Carcinoma.
Conan So; M Minhaj Siddiqui. The New England journal of medicine (2018)
PubMed↗DOI↗

Related Entities

HMGCS2

Parent Context

🔬

Parent Analysis

Metabolic reprogramming in neurodegenerative disease

▸Metadata

status	proposed
disease	neurodegeneration
target_gene	HMGCS2
target_pathway	None
_schema_version	1
composite_score	0.35

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

719

Outgoing

120

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

The Glial Ketone Metabolic Shunt Hypothesis

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — HMGCS2

💉 Clinical Trials (4)Relevance: 13%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (10)

derives from (6)

🧬 Related Hypotheses — same target / disease (6)

💬 Discussion

Composite		61%
Mech.		50%
Evidence		50%
Novelty		50%
Feasibility		50%
Impact		50%
Druggability		50%
Safety		50%
Competition		50%
Data avail.		50%
Reproducibility		50%

📗 Cite This Artifact

The Glial Ketone Metabolic Shunt Hypothesis

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — HMGCS2

💉 Clinical Trials (4)Relevance: 13%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

associated with (2)

causal extracted (1)

co discussed (24)

interacts with (2)

🔮 Predictions

📖 References (10)

derives from (6)

🧬 Related Hypotheses — same target / disease (6)

💬 Discussion